Charles River Laboratories International (NYSE:CRL) Issues FY 2025 Earnings Guidance

Charles River Laboratories International (NYSE:CRL - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 9.300-9.800 for the period, compared to the consensus estimate of 9.310. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.8 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research note on Wednesday, April 9th. Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a research note on Monday, March 3rd. UBS Group reissued a "neutral" rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Robert W. Baird raised their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $176.00.

Charles River Laboratories International Trading Down 1.8 %

CRL stock traded down $2.52 during midday trading on Friday, reaching $138.84. 920,260 shares of the company's stock traded hands, compared to its average volume of 966,135. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The business has a 50-day moving average price of $138.40 and a two-hundred day moving average price of $166.46. The company has a market capitalization of $6.82 billion, a P/E ratio of 925.60, a PEG ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter in the previous year, the business posted $2.27 EPS. The business's quarterly revenue was down 2.7% on a year-over-year basis. Equities research analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Insider Activity

In other news, CEO James C. Foster purchased 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).